Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
on 11-25-2008
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
Here’s the ribbon breaking ceremony picture. Let’s all hope this is a success and hopefully some new technology will enter the picture as well with remote batch monitoring of products manufactured in China and other locations in the world. There is only so much an in person visit can cover...
Posted to
The Medical Quack .... by Barbara Duck
on 11-19-2008
Filed under: Medically Related, Technology, Pharma/FDA News, Pharma, FDA, China, Outsourcing, Tainted Food, food contamination, food safety, busines intelligence software, server banks, import/exports, FDA inspections
The company has formed a “strategic partnership” with inVentiv Health , who does a lot of outsourcing for big Pharma, earlier this year, so perhaps some the sales and marketing slated for sales will be moving in this direction. Merck is not the only company investigating and pursuing this direction...
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
Not just India, but other countries as well. I have posted many articles on the blog referencing outsourcing over the last year or so and all of Big Pharma has interests in foreign countries including the strong possibility of phase 1 clinical trials. The one comment I have to make here...
It appears from the article that the move is generated more towards called made on family practice physicians, as vaccines or drugs marketed to oncologists, ophthalmologists, or dermatologists will still be handled by in house sales representatives, so specialty drug representatives appear to be safe...
Helpful news for the former employees of Amgen, they get an extension on paying off a 2nd mortgage, but some feel this will help, but still not perhaps save the boat. Pharma layoffs in recent years have primarily been in the area of sales and marketing; however now with mergers, acquisitions...